In a report released today, Robbie Marcus from J.P. Morgan maintained a Buy rating on Medtronic (MDT), with a price target of $115.00. The company’s shares closed last Thursday at $101.57.
According to TipRanks.com, Marcus is a 5-star analyst with an average return of 11.7% and a 52.4% success rate. Marcus covers the Healthcare sector, focusing on stocks such as SmileDirectClub, Glaukos, and Inogen.
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $115.93, which is a 16.5% upside from current levels. In a report issued on March 25, DZ BANK AG also upgraded the stock to Buy with a $90.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $122.15 and a one-year low of $72.13. Currently, Medtronic has an average volume of 7.08M.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MDT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.
